Powered by

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7(TM) with Merck's KEYTRUDA® in Triple-Negative Breast Cancer

Apr 26, 2019 - Business Wire

Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7(TM), their T cell amplifier, in combination with Merck's anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast cancer (TNBC).

In June 2018, this study was selected as a grantee of 'Joint R&D Program' supp...